158 related articles for article (PubMed ID: 17115114)
1. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer.
Bagadi SA; Prasad CP; Srivastava A; Prashad R; Gupta SD; Ralhan R
Breast Cancer Res Treat; 2007 Sep; 104(3):277-86. PubMed ID: 17115114
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
3. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
4. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
5. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
[TBL] [Abstract][Full Text] [Related]
6. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation.
Zhao C; Lam EW; Sunters A; Enmark E; De Bella MT; Coombes RC; Gustafsson JA; Dahlman-Wright K
Oncogene; 2003 Oct; 22(48):7600-6. PubMed ID: 14576822
[TBL] [Abstract][Full Text] [Related]
7. Disabled-2 inactivation is an early step in ovarian tumorigenicity.
Fazili Z; Sun W; Mittelstaedt S; Cohen C; Xu XX
Oncogene; 1999 May; 18(20):3104-13. PubMed ID: 10340382
[TBL] [Abstract][Full Text] [Related]
8. A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition.
Pampalakis G; Prosnikli E; Agalioti T; Vlahou A; Zoumpourlis V; Sotiropoulou G
Cancer Res; 2009 May; 69(9):3779-87. PubMed ID: 19383923
[TBL] [Abstract][Full Text] [Related]
9. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation.
Evron E; Umbricht CB; Korz D; Raman V; Loeb DM; Niranjan B; Buluwela L; Weitzman SA; Marks J; Sukumar S
Cancer Res; 2001 Mar; 61(6):2782-7. PubMed ID: 11289162
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
[TBL] [Abstract][Full Text] [Related]
12. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
Noetzel E; Rose M; Sevinc E; Hilgers RD; Hartmann A; Naami A; Knüchel R; Dahl E
Oncogene; 2010 Aug; 29(34):4814-25. PubMed ID: 20543860
[TBL] [Abstract][Full Text] [Related]
13. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers.
Chen ST; Lin SY; Yeh KT; Kuo SJ; Chan WL; Chu YP; Chang JG
Int J Mol Med; 2004 Oct; 14(4):577-82. PubMed ID: 15375584
[TBL] [Abstract][Full Text] [Related]
14. Silencing of LRRC49 and THAP10 genes by bidirectional promoter hypermethylation is a frequent event in breast cancer.
De Souza Santos E; De Bessa SA; Netto MM; Nagai MA
Int J Oncol; 2008 Jul; 33(1):25-31. PubMed ID: 18575747
[TBL] [Abstract][Full Text] [Related]
15. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
[TBL] [Abstract][Full Text] [Related]
16. Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells.
Sheng Z; Sun W; Smith E; Cohen C; Sheng Z; Xu XX
Oncogene; 2000 Oct; 19(42):4847-54. PubMed ID: 11039902
[TBL] [Abstract][Full Text] [Related]
17. Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity.
Yang DH; Smith ER; Cohen C; Wu H; Patriotis C; Godwin AK; Hamilton TC; Xu XX
Cancer; 2002 May; 94(9):2380-92. PubMed ID: 12015763
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation does not account for the frequent loss of the retinoic acid receptor beta2 in breast carcinoma.
Yang Q; Sakurai T; Yoshimura G; Mori I; Nakamura M; Nakamura Y; Suzuma T; Tamaki T; Umemura T; Kakudo K
Anticancer Res; 2001; 21(3B):1829-33. PubMed ID: 11497266
[TBL] [Abstract][Full Text] [Related]
19. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis.
Capo-Chichi CD; Smith ER; Yang DH; Roland IH; Vanderveer L; Cohen C; Hamilton TC; Godwin AK; Xu XX
Cancer; 2002 Oct; 95(8):1802-15. PubMed ID: 12365030
[TBL] [Abstract][Full Text] [Related]
20. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer.
Zhang Z; Huettner PC; Nguyen L; Bidder M; Funk MC; Li J; Rader JS
Oncogene; 2006 Aug; 25(39):5436-45. PubMed ID: 16607278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
